What specific biotech collaboration initiative did BioNexus Gene Lab propose between Malaysia and China, and where was it announced?

BioNexus Gene Lab proposed increased biotechnology co-development between Malaysia and China, specifically advocating for the establishment of regional precision healthcare platforms—including a 'precision healthcare corridor'—and leveraging cross-border commercialization models. These proposals were formally highlighted at the 2026 China–Malaysia Economic Cooperation Outlook Forum held in Kuala Lumpur.

According to BioNexus Gene Lab, how would a Nasdaq listing support its biotech platform development goals?

BioNexus Gene Lab stated that a Nasdaq listing—combined with robust public-market governance—could accelerate the development of its biotech platforms and enhance the credibility of its partners.

BioNexus Gene Lab Urges Malaysia–China Co-Development of Biotech Platforms After Kuala Lumpur Forum

Jun 5, 2026

BioNexus Gene Lab urged Malaysia-China biotech co-development at the 2026 China-Malaysia Economic Cooperation Outlook Forum, proposing a precision healthcare corridor. The firm noted that a Nasdaq listing could accelerate platform development and enhance partner credibility.

TradingView

2026-02-23

BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman

2026-03-12

BioNexus Gene Lab Corp. Appoints Dr. Muthu Meyyappan as CCO of Fidelion Diagnostics to Lead VitaGuard™ MRD Commercialization

2026-04-04

BioNexus Gene Lab Corp Stock Drops 3% on Poor Ratings

2026-04-14

BioNexus Gene Lab 10-K: Revenue $7.42M, EPS $(1.61)

2026-05-15

BioNexus Gene Lab Corp Q1 2026 Earnings: Revenue $22.84K, EPS ($0.23)